Tuesday, September 15, 2015
Guidelines For Chronic Kidney Disease Diagnosis Cause Debate Among Physicians.
Monday, September 14, 2015
Aggressive Blood-Pressure Reduction May Reduce Cardiovascular Problems, Deaths.
During its Friday broadcast, NBC Nightly News (9/11, story 7, 2:05, Snow) reported, “The National Institutes of Health said today that more aggressively lowering target blood pressure would cut the death rate by a staggering 25 percent.”
In a 1,200-word story on its front page, the New York Times(9/12, A1, Kolata, Subscription Publication) reported that in the study, researchers “randomly assigned more than 9,300 men and women ages 50 and over who were at high risk of heart disease or had kidney disease to one of two systolic blood pressure targets: less than 120 millimeters of mercury, which is lower than any guideline ever suggested, or less than 140.” The researchers “found that patients who were assigned to reach a systolic blood pressure goal below 120 — far lower than current guidelines of 140, and 150 for people over 60 — had their risk of heart attacks, heart failure and strokes reduced by a third and their risk of death reduced by nearly a quarter.”
The AP (9/12, Neergaard) reported that “the benefit was strong enough that NIH stopped the study about a year early.”
The Wall Street Journal (9/12, A1, Armao, Whalen, Subscription Publication) reported on its front page that during a conference call during which the findings were announced, Dr. Gary H. Gibbons, director of the National Heart, Lung and Blood Institute, said, “More intensive management of high blood pressure in people 50 years and older can save lives and reduce cardiovascular complications, such as heart attacks.” Gibbons added, “This new important information has the potential to benefit a portion of the estimated one in three adults in the United States who suffer from high blood pressure, as well as millions of others worldwide.”
On its front page, the Washington Post (9/12, A1, Bernstein) points out that “the NHBLI was the primary sponsor of the” research. In a statement, Dr. Gibbons said, “This study provides potentially lifesaving information that will be useful to health care providers as they consider the best treatment options for some of their patients, particularly those over the age of 50.”
USA Today (9/12, Szabo) reported, however, that “NIH researchers did not provide any details about how many lives were saved or the side effects of lowering blood pressure so dramatically.”
Also covering the story were Reuters (9/12, Berkrot), Forbes (9/12, Hedgecock), the NPR (9/12, Stein) “Shots” blog, Newsweek (9/12, Firger), CNN (9/12, Capelouto, Goldschmidt), the Huffington Post (9/12), TIME (9/12, Luckerson), Medscape (9/12, O'Riordan), and HealthDay(9/12, Thompson, Reinberg).
Sunday, September 13, 2015
Metformin potentially underused among patients with mild kidney disease, study finds
More patients would be eligible for metformin use if estimated glomerular filtration rate (eGFR) were used to define kidney disease rather than serum creatinine (sCr), a recent study concluded.
Researchers used data from the 1999 to 2010 National Health and Nutrition Examination Survey (NHANES) to analyze 3,902 adult participants with diabetes (defined by self-report or an HbA1c ≥6.5%) who reported a routine site for health care. Results were published online on Aug. 25 by Diabetes Care.
Across all 12 years, 66.4% of adults with diabetes were treated with a diabetes medication, and this percentage increased over time, from 61.3% in 1999 to 2000 to 69.7% in 2009 to 2010. Metformin use among those with diabetes and a routine site for health care increased from 26.1% to 44.5%.
Among NHANES adults with diabetes and routine care access, 8.8% were ineligible for metformin because of the FDA's contraindication among individuals with sCr ≥1.4 mg/dL for women and ≥1.5 mg/dL for men. Compared with those who were eligible for the drug, those ineligible were older and more likely to be non-Hispanic black or to have a yearly family income less than $45,000.
Researchers also looked at the patients using (eGFR) categories: likely safe to take metformin, ≥45 mL/min/1.73 m2; contraindicated, <30 mL/min/1.73 m2; and indeterminate, 30 to 44 mL/min/1.73 m2. Evidence has shown eGFR to be a more accurate estimate of kidney function than sCr, the authors noted.
Among individuals ineligible for metformin using conventional sCr thresholds, 14.6% had an eGFR ≥45 mL/min/1.73 m2 and 50% had an eGFR between 30 and 44 mL/min/1.73 m2. Only 35.7% of study participants would be ineligible for metformin based on an eGFR <30 mL/min/1.73 m2.
Based on these results, just by adding those for whom metformin is safe according to eGFR criteria, the researchers estimated the number of individuals eligible for metformin in the U.S. can be expanded by between 86,900 and 834,800 people, depending on which method is used to estimate GFR. Most of the potentially eligible patients are male and non-Hispanic blacks. This figure does not take into account the population with eGFR of indeterminate safety (30 to 44 mL/min/1.73 m2), which could range from 784,700 to 1,636,000 people. A randomized controlled trial is needed to clarify whether metformin use in this subgroup would be safe and efficacious, the authors noted.
Limitations of the study are that NHANES is not a clinical database, although the researchers restricted the study population to those who self-reported a routine site for health care. They also noted that they could not determine the reasoning behind low levels of metformin use, which could include non-renal clinical conditions that contraindicate the use of metformin, such as liver disease.
Friday, August 14, 2015
Pioglitazone use not associated with increased risk of bladder cancer, study finds
Pioglitazone was not found to be associated with a statistically significant increased risk of bladder cancer or 8 of 10 additional cancers in a recent study.
In a large, long-term study, researchers analyzed pioglitazone use and associated risks of the following cancers: bladder, prostate, female breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rectum, and melanoma. Results were published on July 21 by the Journal of the American Medical Association.
Of 193,099 people studied, 34,181 (18%) received pioglitazone and 1,261 had incident bladder cancer. Crude incidences of bladder cancer in users and nonusers were 89.8 and 75.9 per 100,000 person-years, respectively, and ever having taken pioglitazone was not associated with bladder cancer risk (adjusted hazard ratio [HR], 1.06; 95% CI, 0.89 to 1.26). However, the study cannot exclude up to a 54% increased risk of bladder cancer, the authors noted.
Use of other diabetes medications, such as metformin, sulfonylureas, insulin, and other thiazolidinediones, was also not significantly associated with bladder cancer risk, with adjusted HRs ranging from 0.91 to 1.09, according to the study.
Although use of pioglitazone was not associated with 8 of 10 additional cancers in adjusted analyses of 236,507 people (HRs ranged from 0.81 to 1.15), use of the medication was associated with increased risk of prostate cancer (HR, 1.13; 95% CI, 1.02 to 1.26) and pancreatic cancer (HR, 1.41; 95% CI, 1.16 to 1.71). Crude incidences of the cancers in pioglitazone users and nonusers were 453.3 versus 449.3 for prostate and 81.1 versus 48.4 for pancreatic per 100,000 person-years. "The increased prostate and pancreatic cancer risks associated with ever use of pioglitazone merit further investigation to assess whether they are causal or are due to chance, residual confounding, or reverse causality," the study authors wrote.
Use of insulin was associated with a decreased risk of prostate cancer (HR, 0.90; 95% CI, 0.81 to 0.99). Use of metformin (HR, 1.21; 95% CI, 1.02 to 1.43), insulin (HR, 2.34; 95% CI, 1.97 to 2.78), and sulfonylureas (HR, 1.49; 95% CI, 1.22 to 1.81) and never having 2 prescriptions of a diabetes medication from the same class within 6 months (HR, 1.55; 95% CI, 1.02 to 2.36) were each associated with increased risk of pancreatic cancer. The fact that other diabetes medications were also associated with an increased risk of pancreatic cancer suggests reverse causality because hyperglycemia is an early manifestation of the cancer, the authors wrote.
The researchers noted that their observational study has potential for unmeasured confounding; has limited statistical power for subgroup analyses related to time since initiation, dose, and duration; and could not exclude all patients with type 1 diabetes (although they minimized this by excluding those under 40).
Wednesday, July 15, 2015
New warnings required for nonaspirin NSAIDs
The FDA issued a safety alert last week regarding cardiovascular warnings for nonaspirin NSAIDs.
Prescription NSAIDs have carried warnings about heart attack and stroke risk since 2005. After reviewing new safety information, the FDA decided to strengthen the existing warning and require that all labels for prescription NSAIDs include the following information:
- The risk of heart attack or stroke can occur as early as the first weeks of NSAID use; it may increase with longer use and appears to be greater at higher doses.
- All NSAIDs were previously thought to have a similar risk for heart attack or stroke. Newer information makes this less clear but is not sufficient for the FDA to determine that any particular NSAID definitely has a higher or lower risk than any other.
- NSAIDs can increase the risk of heart attack or stroke in patients with or without heart disease or heart disease risk factors.
- In general, patients with heart disease or risk factors for heart disease have a greater likelihood of heart attack or stroke after NSAID use than patients without these risk factors because their baseline risk is higher.
- Patients treated with NSAIDs after a first heart attack were more likely to die in the first year afterward than those who were not treated with NSAIDs after their first heart attack.
- Heart failure risk is increased with NSAID use.
The agency is also requesting that these changes be made to the labels of over-the-counter nonaspirin NSAIDs.
The FDA recommended that patients and health care professionals remain alert for heart-related side effects the entire time NSAIDs are taken. Patients who are taking NSAIDs should seek medical attention immediately if they experience such symptoms as chest pain, shortness of breath or trouble breathing, weakness in one part or side of their body, or slurred speech, the FDA said.
The safety alert, which was issued July 9, is available online.
Tuesday, June 2, 2015
ACE inhibitors, ARBs most effective against ESRD in patients with diabetes, kidney disease
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) appear most effective in preventing end-stage renal disease (ESRD) in patients with diabetes and kidney disease, although no regimen to lower blood pressure seems to prolong survival, a recent analysis has found.
Researchers performed a network meta-analysis of randomized trials comparing the effects of oral blood pressure-lowering agents in adults who had diabetic kidney disease. The primary outcomes were all-cause mortality and ESRD; secondary safety and cardiovascular outcomes were also assessed. All drug regimens were ranked comparatively against placebo. The study results were published online on May 23 by The Lancet.
Overall, 157 studies involving 43,256 patients were included in the meta-analysis. The mean patient age was 52.5 years. The drug classes compared with placebo or standard treatment were ACE inhibitors, ARBs, aldosterone antagonists, beta-blockers, calcium-channel blockers, endothelin inhibitors, and renin inhibitors. None of the drug regimens examined appeared to be more effective in reducing all-cause mortality. ESRD was significantly less likely in patients treated with an ARB and an ACE inhibitor (odds ratio, 0.62; 95% CI, 0.43 to 0.90) and in those treated with only an ARB (odds ratio, 0.77; 95% CI, 0.65 to 0.92) versus those treated with placebo.
Hyperkalemia and acute kidney injury did not appear to increase significantly with any regimen (calcium-channel blocker, beta-blocker, ACE inhibitor plus diuretic, endothelin inhibitor, diuretic, renin inhibitor, ARB, ACE inhibitor, aldosterone antagonist, and ACE inhibitor plus ARB for hyperkalemia; ACE inhibitor plus calcium-channel blocker, calcium-channel blocker, ACE inhibitor, renin inhibitor, endothelin inhibitor, ARB, aldosterone antagonist, and ACE inhibitor plus ARB for acute kidney injury). However, the authors noted that ACE inhibitor plus ARB was the regimen with the highest odds ratios for these 2 outcomes (odds ratios, 2.69 [95% CI, 0.97 to 7.47] and 2.69 [95% CI, 0.98 to 7.38]).
The authors noted that their study had limited primary data, that data for the ESRD outcome came mainly from patients with macroalbuminuria and patients with type 2 diabetes, and that acute kidney injury was not well defined, among other limitations. They concluded that based on available evidence, lowering blood pressure in adults with diabetes and kidney disease does not appear to improve survival but that ACE inhibitors and ARBs, together or alone, appear most effective in preventing ESRD in this population.
"However, we must consider the potential harms of these treatments in individual patients," the authors wrote. "Surveillance for treatment-related acute kidney injury and hyperkalaemia is important, as is better standardisation of the definitions of these adverse events and improved understanding of their outcomes, particularly in the context of future trials." They also noted that their results don't support the use of beta-blockers, calcium-channel blockers, renin inhibitors, or diuretic monotherapy in this patient population.
The authors of an accompanying comment said that the results "reignite the debate" about the utility of dual renin-angiotensin-aldosterone system (RAAS) blockade and said that the findings will help researchers design future trials examining this question. The comment authors pointed out that preventive treatments for end-stage kidney failure are urgently needed in diabetic patients.
"Screening for albuminuria and prompt initiation of lifestyle and pharmacological interventions is likely to prevent progression of chronic kidney disease and cardiovascular disease," they wrote. "Addition of dual ACE inhibitor and ARB treatment to this multifactorial management approach—if confirmed to be efficacious and cost effective—might further improve patients' outcomes in regions of the world where careful selection of patients and close monitoring are possible."
Saturday, May 16, 2015
Power Down in May for National High Blood Pressure Education Month
Reducing high blood pressure can lower your risk for stroke and heart attack.
Less is better in some things, including in blood pressure. About 1 of 3 US adults—67 million people—have high blood pressure.1High blood pressure makes your heart work too hard and increases your risk of heart disease and stroke.
You can have high blood pressure and not know it. That is why it is called the silent killer. It is also why it is so important to have your blood pressure checked. If you know family or friends who haven't had their blood pressure checked recently, make it a point to ask them to do it in May, National High Blood Pressure Education Month.
It is easy to check blood pressure and it is painless. It can be checked by your doctor, and many pharmacies have free screenings.
Caution! Arteries Under Pressure
Blood pressure is the force of blood on the walls of your blood vessels as blood flows through them. This pressure naturally rises and falls during the day, but when it is consistently too high, it is considered high blood pressure. The medical term is hypertension.
Like the pipes in your house, your arteries can fail if they are under too much pressure. The video, "High Blood Pressure Basics," illustrates the concept of high blood pressure.
More than 360,000 American deaths in 2010 included high blood pressure as a primary or contributing cause.2 That's 1,000 deaths each day.
Blood pressure has two numbers, systolic and diastolic, and is measured in millimeters of mercury (mmHg). Systolic pressure (the top number) is the force on the blood vessel walls when the heart beats and pumps blood out of the heart. Diastolic pressure (the bottom number) is the force that occurs when the heart relaxes in between beats.
If your blood pressure is less than 120 systolic and less than 80 diastolic, then your blood pressure is normal; between 120 and 139 systolic and 80–89 diastolic, you have prehypertension. Systolic of 140 or greater, or diastolic that is 90 or greater, is hypertension.
What Is Your Risk?
Men and women are about equally likely to develop high blood pressure over their lifetimes, but their risks vary at different ages. The condition affects more men than women before 64 years of age. For people aged 65 years or older, more women than men have high blood pressure.
Age | Men (%) | Women (%) |
|---|---|---|
| 20–34 | 9.1 | 6.7 |
| 35–44 | 24.4 | 17.6 |
| 45–54 | 37.7 | 37.7 |
| 55–64 | 52.0 | 52.0 |
| 65–74 | 63.9 | 70.8 |
| 75+ | 72.1 | 80.1 |
Data in this table are from the 2014 AHA Statistical Update, using 2007-2010 NHANES
African Americans develop high blood pressure more often, and at an earlier age, than whites and Hispanics do. More black women than men have high blood pressure.3
Racial or Ethnic Group | Men (%) | Women (%) |
|---|---|---|
| Blacks | 40.5 | 44.3 |
| Mexican Americans | 28.6 | 27.8 |
| Whites | 31.1 | 28.1 |
| All | 31.3 | 29.6 |
Data in this table are from Health US 2012, using 2007-2010 NHANES
African American men are disproportionately affected by cardiovascular disease (CVD). One of the reasons for this has to do with the rates of uncontrolled high blood pressure among African American men. Uncontrolled high blood pressure among African American men aged 20 years and older is 59.7%; compared to 47.0% of white men. Uncontrolled hypertension among African American women is 47.3% compared to 43.2% for white women.2
Eliminating health disparities among various segments of the population is a CDC priority and a Healthy People 2010 goal.
Keep It Down in There!
If you have high blood pressure, there are steps you can take to get it under control, including—
- Ask your doctor what your blood pressure should be.Set a goal to lower your pressure with your doctor and then discuss how you can reach your goal. Work with your health care team to make sure you meet that goal.
- Take your blood pressure medication as directed. If you are having trouble, ask your doctor what you can do to make it easier. For example, you may want to discuss your medication schedule with your doctor if you are taking multiple drugs at different times of the day. Or you may want to discuss side effects you are feeling, or the cost of your medicine.
- Quit smoking—and if you don't smoke, don't start.You can find tips and resources at CDC's Smoking and Tobacco Web site or Be Tobacco Free Web site.
- Reduce sodium. Most Americans consume too much sodium, and it raises blood pressure in most people. Learn about tips to reduce your sodium.
There are other healthy habits, that can help keep your blood pressure under control—
- Achieve and maintain a healthy body weight.
- Participate in 30 minutes of moderate physical activity on most days of the week.
- Eat a healthy diet that is high in fruits and vegetables and low in sodium, saturated fats, trans fat, and cholesterol.
- Manage stress.
- Limit the amount of alcohol you drink (no more than one drink each day for women and two for men).
- If you have high blood pressure and are prescribed medication, take it as directed.
- If you have a family member who has high blood pressure, you can help by taking many of the steps listed above with them. Go for walks together or cook meals with lower sodium. Make it a family affair!
- Check your blood pressure regularly.
Resources
The Dietary Approaches to Stop Hypertension (DASH) can help control high blood pressure through a healthy diet.
"I can do it!" is the message of the My Blood Pressure Wallet Card that helps patients monitor their blood pressure readings, remember to take their medications, and keep up the lifestyle changes that will help lower their blood pressure.
Million Hearts® is a national initiative to prevent 1 million heart attacks and strokes in the United States by 2017. Launched by the US Department of Health and Human Services (HHS), it aligns existing efforts and creates new programs to help Americans live longer, more productive lives. The CDC and Centers for Medicare and Medicaid Services, co-leaders of Million Hearts™ within HHS, are working alongside other federal agencies and private-sector organizations to make a long-lasting impact against cardiovascular disease.
References
- CDC. Vital signs: awareness and treatment of uncontrolled hypertension among adults—United States, 2003–2010. MMWR. 2012;61:703-9.
- Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation.2014;129:e28-e292.
- CDC. Health, United States, 2012: With Special Feature on Emergency Care. Atlanta, GA: US Department of Health and Human Services; 2013.
- CDC. A Closer Look at African American Men and High Blood Pressure Control: A Review of Psychosocial Factors and Systems-Level Interventions. Atlanta, GA: US Department of Health and Human Services; 2010.
